Introduction
Rheumatoid arthritis is a chronic systemic articular inflammatory disorder of unknown aetiology. The disease is characterized by symmetric polyarthritis of mainly the hands and the feet. Chronic pain, stiffness and loss of functional capacity are major features of rheumatoid arthritis. In about 10% of the patients the disease runs a progressive course with destructive polyarthritis leading to considerable disability and frequent presence of extra-articular manifestations such as vasculitis, pleuritis etc. T-lymphocytes play an important part in the complex process of immune and inflammatory events in rheumatoid arthritis.
The therapeutic goals of the treatment of rheumatoid arthritis are threefold: decrease of pain, decrease of stiffness, and prevention or slowing of articular damage. The first-line antirheumatic agents (nonsteroidal anti-inflammatory drugs; NSAID's) are often insufficiently effective, but remain the drugs of first choice. Persistence of polyarthritis despite 2-3 months of therapy with NSAID's, is an indication to add second-line antirheumatic agents (disease-modifying antirheumatic drugs; DMARD's). Examples of DMARD's are hydroxychloroquine, parenteral and oral gold compounds, penicillamine, salazopyrine, azathioprine and methotrexate. In comparison with NSAID's, several DMARD's are able to retard the disease course to a greater or lesser extent.
Recently it was shown that radiologic damage was already present in the majority of rheumatoid arthritis patients within two years after the diagnosis. So there is a growing trend to introduce second-line antirheumatic agents sooner in order to slow articular damage earlier.
The main objective of the present studies was to investigate the place of low-dose methotrexate in the treatment of severe rheumatoid arthritis with emphasis on the clinical aspects. To this purpose a doubleblind, randomized trial with azathioprine was conducted.
Azathioprine
Azathioprine is a nitro-imidazole derivative of mercaptopurine. The elimination half-life (ti12) is relatively short (0.2-I h). The plasma protein binding is about 30% and its apparent volume of distribution 0.8 I/kg. Both azathioprine and mercaptopurine are purine analogues and inhibit DNA and RNA synthesis after conversion to their ribonucleotides. The usual dosage of azathioprine in the treatment of rheumatoid arthritis ranges from 1.5 to 2.5 mg/kg daily.
The metabolism of azathioprine follows three important enzymatic routes of which the conversion by hypoxanthine guanine phosphoribosyl transferase (HGPRT) is the major one. Inherited low thiopurine methyl transferase (TPMT) activity constitutes a major risk of developing of azathioprine-induced myelosuppression. Concurrent use of azathioprine and allopurinol, a known xanthine oxidase inhibitor, may also lead to myelosuppression.
The exact mechanism of action of azathioprine in rheumatoid arthritis is unclear. Compared with placebo there is a proven clinical antirheumatic effect of azathioprine. Double-blind studies of azathioprine versus other DMARD's have not revealed significant intergroup differences with regard to clinical effects and adverse reactions.
Gastrointestinal side-effects and leucopenia are the most frequent adverse reactions. Less frequent sideeffects are hepatotoxicity, hypersensitivity reactions, and haematologic complications.
Methotrexate
Methotrexate is an antagonist of folate-dependent enzymes of which dihydrofolate reductase (DHFR) is the most important target enzyme. Folate-dependent enzymes are involved in DNA and RNA synthesis.
The usual dose of methotrexate in rheumatoid arthritis ranges between 7,5-15 mg per week either in one single dose or in a divided dose (3 • 2.5 mg within 24 h). The absorption of low-dose methotrexate is less than 50%. The mean bioavailibility is 73%. Pharmacokinetic studies of low-dose methotrexate reveal a biphasic disappearance with an initial tll 2 of 0.1-1.2 h and a terminal tl/2 of 4.5-6.5 h. Renal excretion is the major route of methotrexate elimination. Patients with decreased renal function (clearance < 50 ml/min) have an increased risk of adverse reactions to methotrexate. Concurrent use of NSAID's and low-dose methotrexate in rheumatoid arthritis rarely causes serious drug interactions except in the case of decreased renal function. The use of methotrexate concomitantly with other antifolate drugs such as trimethoprim and trimethoprim plus sulfamethoxazole (co-trimoxazole) is contraindicated in view of potentially lethal myelosuppression.
In vitro and in vivo studies suggest that low-dose methotrexate has anti-inflammatory, subtle immunomodulating and antiproliferative properties. The exact mechanism in rheumatoid arthritis, however, remains unclear. Double-blind trials of methotrexate compared with either placebo or other DMARD's 27
have proven the clinical efficacy of methotrexate in rheumatoid arthritis beyond all doubt. The most frequent adverse reactions of methotrexate are elevated liver enzymes and gastrointestinal side-effects. Less frequent adverse reactions are stomatitis, haematological and pulmonary (pneumonitis) side-effects. There is much debate about the need for liver biopsies after 1.5-2.0 g methotrexate cumulatively.
Open (pilot) study 16 Patients with active rheumatoid arthritis refractory to hydroxychloroquine, aurothioglucose, penicillamine and azathioprine were enrolled in an open 12 month study. Patients received 7.5 mg methotrexate weekly and, depending on their clinical response after 8 weeks, 15 mg methotrexate weekly. All patients had used NSAID's and 8 patients also used prednisone (_<10 mg daily) before the study. 14 Patients completed 6 months and 12 completed 12 months of therapy.
After 6 months there was significant (p _< 0.05) improvement of morning stiffness, tender joints, Ritchie articular index, swollen joints and pain score. Furthermore, some laboratory values improved, such as erythrocyte sedimentation rate (ESR) and Creactive protein (CRP). The clinical improvement began as early as ] month after the start of the medication and increased until up to 6 months. Between 6 and 12 months there was no further improvement. Articular indices improved by 50% compared with baseline values.
Side-effects (gastrointestinal, 31%; elevated liver enzymes, 25%) occurred, but were mostly mild. The general conclusion was that methotrexate was an effective antirheumatic drug in severe, refractory rheumatoid arthritis.
Double-blind study
Clinical results 64 Patients with active rheumatoid arthritis were randomly assigned to receive 7.5 mg methotrexate weekly or 100 mg azathioprine daily in a 48-week, randomized, double-blind study. Depending on the clinical effect after 8 weeks, the dosage was increased to either 15 mg methotrexate weekly, or 150 mg azathioprine daily. The dosages of NSAID's and prednisone (-< 10 rag/daily) were held stable. All patients had not responded to or reacted with side-effects to parenteral gold preparations and/or penicillamine. Apart from the change in separate clinical and laboratory variables, the change in a validated composed index of four variables (disease-activity.score; DAS) was also calculated.
Comparison of 24-week values with baseline values revealed significant (p < 0.05) improvement in 12 of 13 clinical and laboratory variables in the methotrexate group and 6 of 13 in the azathioprine group. Patients from the methotrexate group showed significantly more improvement in the following seven variables: pain score, swollen-joint count, erythrocyte sedimentation rate, C-reactive protein, haemoglobin level, thrombocyte level, and the disease-activity score. A significant overall clinical improvement was found in 7 of 20 (32%) patients treated with azathioprine and 18 of 30 (60%) patients treated with methotrexate after 24 weeks of therapy, and in 6 of 12 azathioprine-treated (50%) patients and 19 of 25 (76%) methotrexate-treated patients after 48 weeks.
The number of withdrawals due to side-effects was significantly higher in the azathioprine group (13 versus 2 in the methotrexate group). Adverse reactions to azathioprine leading to withdrawal included gastro-intestinal side-effects (5), haematological sideeffects (2), hypersensitivity (3), cholestatic liver dysfunction (2), and central nervous system complications (I). After 48 weeks, only 12 patients from the azathioprine group (36%), but 25 from the methotrexate group (81%), were still using the initial drug. These results have demonstrated clinical superiority of methotrexate to azathioprine.
Radiologic results
The influence of methotrexate and azathioprine on the progression in rheumatoid arthritis as determined radiologically, was investigated in the same patient groups as described in the section Clinical results. Radiographs of hands, wrists and feet obtained at baseline and after 24 and 48 weeks were scored according to the modified method of Sharp by one experienced rheumatologist blinded to the medication and clinical findings. Initial radiologic scores (erosion score and total joint score, i.e. score for erosions plus score for joint space narrowing) were comparable in the two treatment groups. Patients who completed 24 and 48 weeks of the same drug, showed more new erosions when treated with azathioprine than with methotrexate. This difference was significant after 48 weeks. The total radiologic score at 24 and 48 weeks also showed less progression in the methotrexate group.
After an intention-to-treat analysis at 24 and 48 weeks, significantly fewer new erosions and less change in total radiologic score were found in favour of the patients initially treated with methotrexate. Radiologic stabilization after 48 weeks was found in 10% of the azathioprine group and in 29% of the methotrexate group. The favourable radiologic results of methotrexate probably reflect the earlier response and more pronounced clinical effect of methotrexate.
Pulmonary function tests
In the same patient groups as mentioned before, it was investigated whether periodic pulmonary function tests and chest radiographs were useful for detecting methotrexate-induced pulmonary toxicity in rheumatoid arthritis. Extensive pulmonary function tests (spirometry, flow-volume curves, CO diffusion, compliance) and chest radiographs were performed at baseline, after 24 weeks and after 2 years. Results of baseline pulmonary function tests (27 azathioprine and 25 methotrexate patients) showed abnormal results in one or more function tests in 15-50% of patients. After 24 weeks and 2 years, results of pulmonary function tests and chest radiographs showed no changes either within the two groups or between the two groups. Patients with pre-existent lung abnormalities did not develop methotrexate-induced pneumonitis. In view of the prevalence of methotrexate pneumonitis (3-5%), baseline chest radiograph and limited function tests (spirometry, CO diffusion) may nevertheless be advisable.
Adverse drug reactions
Finally, four rare but potentially dangerous complications of azathioprine and methotrexate were found: pancytopenia due to azathioprine; fever, chills, and liver dysfunction due to azathioprine; eruption of nodulosis due to methotrexate; pancytopenia due to the combined use of methotrexate and trimethoprim and trimethoprim+sulfamethoxazole.
In conclusion, in view of the superior clinical effects and radiologic results of methotrexate compared to azathioprine, administering methotrexate before azathioprine is preferable in patients with rheumatoid arthritis.
Introduction
Since its introduction in the early sixties, the loop diuretic furosemide has often been used for the treatment of patients with congestive heart failure (CHF), hepatic/renal failure or nephrotic syndrome. However, despite a large amount of literature, no final conclusion can be drawn regarding the most efficient mode of administration and the maximum effective dose in patients with congestive heart failure. The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of highdose furosemide in patients with congestive heart failure, the most efficient mode of furosemide administration and its implications with respect to CHF patients with diuretic resistance. In addition the pharmacodynamics of high-dose furosemide in haemodialysis patients with residual diuresis were studied.
Absorption of high doses of furosemide in congestive heart failure
Previous studies suggest that malabsorption of furosemide, secondary to changes induced by congestive heart failure could be a cause of diminished response. We studied the influence of the state (compensated or decompensated) of heart failure on absorption pharmacokinetics in 9 patients with severe congestive heart failure (NYHA class Ill-IV) after oral intake of the drug. Theoretically weight reduction could influence absorption kinetics and furosemide pharmacodynamics. Mean weight reduction between the decompensated and the compensated state was 12.0 kg. Individual furosemide plasma concentration-time curves could be adequately fitted to a one-compartment model with first-order absorption and elimination kinetics. The absorption process in these patients could be divided into two distinct phases with different lag times.
We did not find significant differences in pharmacokinetic parameters such as absorption half-life, elimination half-life, time to peak serum concentration, peak concentration itself and area under the plasma concentration-time curve, nor in pharmacodynamics. When these patients were decompensated the first absorption fraction was significantly smaller (31%) compared with the compensated state (65%). As a consequence a larger quantity of furosemide was initially delivered to the kidney in these patients when compensated; however, this had a minor influence on the onset and magnitude of diuresis.
We concluded that the presence of massive oedema in patients with congestive heart failure has only a minor (and, read from this series of patients, clinically irrelevant) influence on the pharmacokinetics and the pharmacodynamics of high oral doses of furosemide. However, it must be stressed that the pharmacokinetics and pharmacodynamics of furosemide are markedly altered in patients with both compensated and decompensated congestive heart failure compared with data obtained from healthy volunteers.
High doses of furosemide in congestive heart failure
The furosemide dose usually recommended for the treatment of congestive heart failure consists of 40 to 120 mg/day, with a maximum single oral or intravenous dose of 200-250 mg. Little is known about the maximum effective dose that can be given safely to patients with congestive heart failure. More ex-29
